GlassScriptPhysician profile
Charles King
NPI 1790134948
$3,657.42
in general payments reported to CMS, 2019-2025
19 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2022: $538 · 2023: $164 · 2024: $861 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,870.74 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,291.48 | 2021-2025 | Caplyta |
| Abbvie INC. | $919.22 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $347.28 | 2024-2025 | Fanapt |
| Alkermes, INC. | $308.61 | 2022-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $148.99 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $137.08 | 2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $100.82 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $97.86 | 2023-2025 | Rexulti |
| Lundbeck LLC | $70.59 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $42.22 | 2022 | |
| Ironshore Pharmaceuticals INC. | $35.66 | 2022 | |
| Novo Nordisk INC | $30.36 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $27.26 | 2022-2024 | Ingrezza |
| Indivior INC. | $21.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.81 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $19.36 | 2025 | Loreev Xr |
| Amgen INC. | $13.90 | 2022 | |
| Braeburn INC. | $13.56 | 2025 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.